Kidney Week is the annual meeting of the American Society of Nephrology (ASN). It offers the opportunity to exchange knowledge and engage with the latest scientific and medical advances in nephrology.
Travere at ASN Kidney Week 2025
Travere Therapeutics was excited to attend ASN Kidney Week 2025 and discuss the latest advancements in nephrology with leading experts in the field.
Program
Patients (Pts) with FSGS Reach Proteinuria <0.7 g/g More Often with Sparsentan (SPAR) vs. Irbesartan (IRB) in DUPLEX: Implications for Kidney Failure (KF) Risk
Speakers: Jai Radhakrishnan, Daniel P. Gale, Rasheed A. Gbadegesin, Jula K. Inrig, Radko Komers, Alex Mercer, Edward Murphy, David Pitcher, and Moin A. Saleem
Type: Summary – Coming Soon
Meet a Travere MSL
Our Medical Science Liaisons (MSLs) are available to answer questions and provide support on Travere products.
Schedule a meetingSparsentan vs Irbesartan in Pediatric Patients With Focal Segmental Glomerulosclerosis (FSGS) in the Phase 3 DUPLEX Trial
Speakers: Michelle N Rheault, Katherine M Dell, Kenneth Lieberman, Kevin Meyers, Ana Paredes, Edward Murphy, Jula Inrig, Radko Komers, and Howard Trachtman
Type: Summary – Coming Soon
Sparsentan (SPAR) in Participants With Focal Segmental Glomerulosclerosis (FSGS) and Collagen Type IV Alpha 3-5 Chain (COL4A3-5) Variants
Speakers: Jennifer Yee, Howard Trachtman, Michelle Rheault, Patricia W Bedard, Angela Gruber, Wu Gong, Radko Komers
Evaluation of Cardiovascular Risk Factors, Structure, and Function in an Interim Analysis of the SPARTAN Study: Sparsentan as First-Line Treatment of Incident Patients With IgA Nephropathy
Speakers: Chee Kay Cheung, Neeraj Dhaun, Sian V. Griffin, Bruce M. Hendry, Alexandra L. Howson, Radko Komers, Alex Mercer, Stephanie Moody, Kelly Parke, Matthew Sayer, Smeeta Sinha, Lisa Willcocks, Jonathan Barratt, Matthew Graham-Brown
The Effect of Sparsentan (SPAR) on Proteinuria and Urinary Inflammatory and Profibrotic Biomarkers by Baseline Proteinuria Strata in SPARTAN Study Participants With IgA Nephropathy (IgAN)
Speakers: Chee Kay Cheung, William A Barratt, Neeraj Dhaun, Siân Griffin, Bruce Hendry, Amal A A Jama, Ishika Khan, Radko Komers, Alex Mercer, Stephanie Moody, Nadia Nawaz, Matthew Sayer, Smeeta Sinha, Lisa Willcocks, Jonathan Barratt
PROTECT Post Hoc Analysis: Efficacy of Sparsentan (SPAR) vs Irbesartan (IRB) in Patients (Pts) With IgA Nephropathy ≤12 mo vs >12 mo From Kidney Biopsy
Speakers: Shikha Wadhwani, Jonathan Barratt, Radko Komers, Stephanie Moody, Vladimir Tesar
Type: Summary – Coming Soon
Estimating the Benefits of Proteinuria Reduction on Kidney Failure Risk in the DUPLEX Study Using Aligned FSGS Cohort From the UK RaDaR Registry
Speakers: Alex Mercer, Daniel P. Gale, Bruce M. Hendry, Radko Komers, Edward Murphy, David Pitcher, Howard Trachtman, Moin A. Saleem
Type: Summary – Coming Soon
Impact of Histology on Efficacy of Sparsentan Therapy in IgA Nephropathy: Central Biopsy Review of Patients in the PROTECT Trial
Speakers: Ian Roberts, Bruce Hendry, Alex Mercer, Stephanie Moody, Edward Murphy, Radko Komers
Case Series: Proteinuria Reductions With Sparsentan (SPAR) Combined With Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2is) in Adults With IgA Nephropathy (IgAN) at a Single Site
Speakers: Ankit Mehta, Gustavo Borda Sanchez, Alexandra R Willcockson, Agness Pelts Block
Real-World Data on Low Proteinuria With Sparsentan (SPAR) in Patients (Pts) With IgA Nephropathy (IgAN): A Case Series
Speakers: Raymond Hsu, Grace Choi, Christie Izutsu, Mohammad Kamgar, Niloofar Nobakht, Basmina Parmakhtiar, Agness Pelts Block, Nasim Wiegley, Lisa Willcocks, Matthias Kretzler, Jonathan Barratt
Outcomes of Renal Transplantation in Primary Glomerulonephritis (GN) Mapped to Post-Transplant Proteinuria in the UK RaDaR Registry
Speakers: Daniel P. Gale, Alex Mercer, Jonathan Barratt, Durga Anil K Kanigicherla, Rachel B. Jones, Thomas Oates, Alan D. Salama, Moin A. Saleem, Sapna Shah, Roslyn J. Simms, A. Neil Turner, Edwin K. Wong, Bruce M. Hendry, David Pitcher
MA-DS-25-0077 | September 2025